title: Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
abstract: We present the case of a 51-year-old man who developed paraneoplastic pemphigus (PNP) in the context of chronic lymphocytic leukemia (CLL). His CLL was successfully controlled with ibrutinib. Concurrently, there was significant improvement of his PNP, suggesting that ibrutinib may be a very useful addition to the treatment options in this potentially life-threatening autoimmune disorder.
authors.affiliation: Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.|Sydney Medical School Northern, University of Sydney, Sydney, New South Wales, Australia.
authors.forename: Andrew
authors.initials: A
authors.lastname: Lee
authors.affiliation: Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.|Northern Blood Research Centre, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
authors.forename: Suneet
authors.initials: S
authors.lastname: Sandhu
authors.affiliation: Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
authors.forename: Louise
authors.initials: L
authors.lastname: Imlay-Gillespie
authors.affiliation: Sydney Medical School Northern, University of Sydney, Sydney, New South Wales, Australia.|Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.|Northern Blood Research Centre, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
authors.forename: Stephen
authors.initials: S
authors.lastname: Mulligan
authors.affiliation: Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.|Sydney Medical School Northern, University of Sydney, Sydney, New South Wales, Australia.
authors.forename: Stephen
authors.initials: S
authors.lastname: Shumack
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000209:etiology*; D010392:Pemphigus / Q000209:etiology*; D010880:Piperidines; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine
keywords: 
  PAMS
  ; chronic lymphocytic leukemia; ibrutinib; paraneoplastic pemphigus